MUC1-mediated metabolic alterations regulate response to radiotherapy in pancreatic cancer

Venugopal Gunda, Joshua Souchek, Jaime Abrego, Surendra K. Shukla, Gennifer D. Goode, Enza Vernucci, Aneesha Dasgupta, Nina V. Chaika, Ryan J. King, Sicong Li, Shuo Wang, Fang Yu, Tadayoshi Bessho, Chi Lin, Pankaj Singh

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose: MUC1, an oncogene overexpressed in multiple solid tumors, including pancreatic cancer, reduces overall survival and imparts resistance to radiation and chemotherapies. We previously identified that MUC1 facilitates growth-promoting metabolic alterations in pancreatic cancer cells. The present study investigates the role of MUC1-mediated metabolism in radiation resistance of pancreatic cancer by utilizing cell lines and in vivo models. Experimental Design: We used MUC1-knockdown and -overexpressed cell line models for evaluating the role of MUC1-mediated metabolism in radiation resistance through in vitro cytotoxicity, clonogenicity, DNA damage response, and metabolomic evaluations. We also investigated whether inhibition of glycolysis could revert MUC1-mediated metabolic alterations and radiation resistance by using in vitro and in vivo models. Results: MUC1 expression diminished radiation-induced cytotoxicity and DNA damage in pancreatic cancer cells by enhancing glycolysis, pentose phosphate pathway, and nucleotide biosynthesis. Such metabolic reprogramming resulted in high nucleotide pools and radiation resistance in in vitro models. Pretreatment with the glycolysis inhibitor 3-bromo-pyruvate abrogated MUC1-mediated radiation resistance both in vitro and in vivo, by reducing glucose flux into nucleotide biosynthetic pathways and enhancing DNA damage, which could again be reversed by pretreatment with nucleoside pools. Conclusions: MUC1-mediated nucleotide metabolism plays a key role in facilitating radiation resistance in pancreatic cancer and targeted effectively through glycolytic inhibition.

Original languageEnglish (US)
Pages (from-to)5881-5891
Number of pages11
JournalClinical Cancer Research
Volume23
Issue number19
DOIs
StatePublished - Oct 1 2017

Fingerprint

Pancreatic Neoplasms
Radiotherapy
Radiation
Glycolysis
Nucleotides
DNA Damage
Cell Line
Pentose Phosphate Pathway
Metabolomics
Biosynthetic Pathways
Pyruvic Acid
Oncogenes
Nucleosides
Research Design
Glucose
Drug Therapy
In Vitro Techniques
Growth
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

MUC1-mediated metabolic alterations regulate response to radiotherapy in pancreatic cancer. / Gunda, Venugopal; Souchek, Joshua; Abrego, Jaime; Shukla, Surendra K.; Goode, Gennifer D.; Vernucci, Enza; Dasgupta, Aneesha; Chaika, Nina V.; King, Ryan J.; Li, Sicong; Wang, Shuo; Yu, Fang; Bessho, Tadayoshi; Lin, Chi; Singh, Pankaj.

In: Clinical Cancer Research, Vol. 23, No. 19, 01.10.2017, p. 5881-5891.

Research output: Contribution to journalArticle

Gunda, V, Souchek, J, Abrego, J, Shukla, SK, Goode, GD, Vernucci, E, Dasgupta, A, Chaika, NV, King, RJ, Li, S, Wang, S, Yu, F, Bessho, T, Lin, C & Singh, P 2017, 'MUC1-mediated metabolic alterations regulate response to radiotherapy in pancreatic cancer', Clinical Cancer Research, vol. 23, no. 19, pp. 5881-5891. https://doi.org/10.1158/1078-0432.CCR-17-1151
Gunda, Venugopal ; Souchek, Joshua ; Abrego, Jaime ; Shukla, Surendra K. ; Goode, Gennifer D. ; Vernucci, Enza ; Dasgupta, Aneesha ; Chaika, Nina V. ; King, Ryan J. ; Li, Sicong ; Wang, Shuo ; Yu, Fang ; Bessho, Tadayoshi ; Lin, Chi ; Singh, Pankaj. / MUC1-mediated metabolic alterations regulate response to radiotherapy in pancreatic cancer. In: Clinical Cancer Research. 2017 ; Vol. 23, No. 19. pp. 5881-5891.
@article{c85fab069a4e4a3f95ec9408b32be93a,
title = "MUC1-mediated metabolic alterations regulate response to radiotherapy in pancreatic cancer",
abstract = "Purpose: MUC1, an oncogene overexpressed in multiple solid tumors, including pancreatic cancer, reduces overall survival and imparts resistance to radiation and chemotherapies. We previously identified that MUC1 facilitates growth-promoting metabolic alterations in pancreatic cancer cells. The present study investigates the role of MUC1-mediated metabolism in radiation resistance of pancreatic cancer by utilizing cell lines and in vivo models. Experimental Design: We used MUC1-knockdown and -overexpressed cell line models for evaluating the role of MUC1-mediated metabolism in radiation resistance through in vitro cytotoxicity, clonogenicity, DNA damage response, and metabolomic evaluations. We also investigated whether inhibition of glycolysis could revert MUC1-mediated metabolic alterations and radiation resistance by using in vitro and in vivo models. Results: MUC1 expression diminished radiation-induced cytotoxicity and DNA damage in pancreatic cancer cells by enhancing glycolysis, pentose phosphate pathway, and nucleotide biosynthesis. Such metabolic reprogramming resulted in high nucleotide pools and radiation resistance in in vitro models. Pretreatment with the glycolysis inhibitor 3-bromo-pyruvate abrogated MUC1-mediated radiation resistance both in vitro and in vivo, by reducing glucose flux into nucleotide biosynthetic pathways and enhancing DNA damage, which could again be reversed by pretreatment with nucleoside pools. Conclusions: MUC1-mediated nucleotide metabolism plays a key role in facilitating radiation resistance in pancreatic cancer and targeted effectively through glycolytic inhibition.",
author = "Venugopal Gunda and Joshua Souchek and Jaime Abrego and Shukla, {Surendra K.} and Goode, {Gennifer D.} and Enza Vernucci and Aneesha Dasgupta and Chaika, {Nina V.} and King, {Ryan J.} and Sicong Li and Shuo Wang and Fang Yu and Tadayoshi Bessho and Chi Lin and Pankaj Singh",
year = "2017",
month = "10",
day = "1",
doi = "10.1158/1078-0432.CCR-17-1151",
language = "English (US)",
volume = "23",
pages = "5881--5891",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "19",

}

TY - JOUR

T1 - MUC1-mediated metabolic alterations regulate response to radiotherapy in pancreatic cancer

AU - Gunda, Venugopal

AU - Souchek, Joshua

AU - Abrego, Jaime

AU - Shukla, Surendra K.

AU - Goode, Gennifer D.

AU - Vernucci, Enza

AU - Dasgupta, Aneesha

AU - Chaika, Nina V.

AU - King, Ryan J.

AU - Li, Sicong

AU - Wang, Shuo

AU - Yu, Fang

AU - Bessho, Tadayoshi

AU - Lin, Chi

AU - Singh, Pankaj

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Purpose: MUC1, an oncogene overexpressed in multiple solid tumors, including pancreatic cancer, reduces overall survival and imparts resistance to radiation and chemotherapies. We previously identified that MUC1 facilitates growth-promoting metabolic alterations in pancreatic cancer cells. The present study investigates the role of MUC1-mediated metabolism in radiation resistance of pancreatic cancer by utilizing cell lines and in vivo models. Experimental Design: We used MUC1-knockdown and -overexpressed cell line models for evaluating the role of MUC1-mediated metabolism in radiation resistance through in vitro cytotoxicity, clonogenicity, DNA damage response, and metabolomic evaluations. We also investigated whether inhibition of glycolysis could revert MUC1-mediated metabolic alterations and radiation resistance by using in vitro and in vivo models. Results: MUC1 expression diminished radiation-induced cytotoxicity and DNA damage in pancreatic cancer cells by enhancing glycolysis, pentose phosphate pathway, and nucleotide biosynthesis. Such metabolic reprogramming resulted in high nucleotide pools and radiation resistance in in vitro models. Pretreatment with the glycolysis inhibitor 3-bromo-pyruvate abrogated MUC1-mediated radiation resistance both in vitro and in vivo, by reducing glucose flux into nucleotide biosynthetic pathways and enhancing DNA damage, which could again be reversed by pretreatment with nucleoside pools. Conclusions: MUC1-mediated nucleotide metabolism plays a key role in facilitating radiation resistance in pancreatic cancer and targeted effectively through glycolytic inhibition.

AB - Purpose: MUC1, an oncogene overexpressed in multiple solid tumors, including pancreatic cancer, reduces overall survival and imparts resistance to radiation and chemotherapies. We previously identified that MUC1 facilitates growth-promoting metabolic alterations in pancreatic cancer cells. The present study investigates the role of MUC1-mediated metabolism in radiation resistance of pancreatic cancer by utilizing cell lines and in vivo models. Experimental Design: We used MUC1-knockdown and -overexpressed cell line models for evaluating the role of MUC1-mediated metabolism in radiation resistance through in vitro cytotoxicity, clonogenicity, DNA damage response, and metabolomic evaluations. We also investigated whether inhibition of glycolysis could revert MUC1-mediated metabolic alterations and radiation resistance by using in vitro and in vivo models. Results: MUC1 expression diminished radiation-induced cytotoxicity and DNA damage in pancreatic cancer cells by enhancing glycolysis, pentose phosphate pathway, and nucleotide biosynthesis. Such metabolic reprogramming resulted in high nucleotide pools and radiation resistance in in vitro models. Pretreatment with the glycolysis inhibitor 3-bromo-pyruvate abrogated MUC1-mediated radiation resistance both in vitro and in vivo, by reducing glucose flux into nucleotide biosynthetic pathways and enhancing DNA damage, which could again be reversed by pretreatment with nucleoside pools. Conclusions: MUC1-mediated nucleotide metabolism plays a key role in facilitating radiation resistance in pancreatic cancer and targeted effectively through glycolytic inhibition.

UR - http://www.scopus.com/inward/record.url?scp=85031414113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031414113&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-17-1151

DO - 10.1158/1078-0432.CCR-17-1151

M3 - Article

C2 - 28720669

AN - SCOPUS:85031414113

VL - 23

SP - 5881

EP - 5891

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 19

ER -